Etanercept - Pfizer

Drug Profile

Etanercept - Pfizer

Alternative Names: Enbrel; p75TNFR-Ig; rhu TNFR-Fc; Soluble tumour necrosis factor receptor p75 Fc IgG1 fusion protein; TNF receptor fusion protein; TNFR-Fc-p75; TNR-001

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Pantec Biosolutions; Pfizer; University of Leeds
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Graft-versus-host disease
  • Phase II Discoid lupus erythematosus
  • No development reported Metabolic syndrome
  • Discontinued Adult-onset Still's disease; Asthma; Behcet's syndrome; Cachexia; Heart failure; Myasthenia gravis; Pulmonary fibrosis; Septic shock; Transplant rejection; Wegener's granulomatosis

Most Recent Events

  • 09 Oct 2017 Amgen completes a phase III trial for Psoriatic arthritis, Rheumatoid arthritis in USA and Puerto Rico (SC) (NCT02986139)
  • 07 Aug 2017 Coherus BioSciences files for Inter Partes Review for Etanercept patent in USA
  • 14 Jul 2017 The UK's NICE recommends etanercept for Plaque psoriasis (In children, In adolescents, ≥ 6 years)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top